Trifluoromethyl ketones as inhibitors of histone deacetylase

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 23, 2002, Pages 3443-3447

  Frey, Robin R ^a   Wada, Carol K ^a   Garland, Robert B ^a   Curtin, Michael L ^a   Michaelides, Michael R ^a   Li, Junling ^a   Pease, Lori J ^a   Glaser, Keith B ^a   Marcotte, Patrick A ^a   Bouska, Jennifer J ^a   Murphy, Shannon S ^a   Davidsen, Steven K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; HISTONE DEACETYLASE INHIBITOR; KETONE DERIVATIVE; ENZYME INHIBITOR; FLUORINATED HYDROCARBON; HISTONE; HISTONE DEACETYLASE; KETONE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FIBROSARCOMA; HUMAN; HUMAN CELL; MITOSIS INHIBITION; REACTION OPTIMIZATION; ACETYLATION; BREAST TUMOR; CELL CULTURE; CELL CYCLE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ACETYLATION; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; ENZYME INHIBITORS; FIBROSARCOMA; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROCARBONS, FLUORINATED; KETONES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 18644379759     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00754-0     Document Type: Article

References (31)

1. Jenuwein T., Allis C.D. Science. 293:2001;1074.
2. (a) Reviews: Krämer O.H., Göttlicher M., Heinzel T. Trends Endocrinol. Metab. 12:2001;294
3. (b) Marks P.A., Richon V.M., Rifkind R.A. J. Natl. Cancer Inst. 92:2000;1210.
4. (a) Kim Y.B., Lee K.-H., Sugita K., Yoshida M., Horinouchi S. Oncogene. 18:1999;2461
5. (b) Jung M., Hoffman K., Brosch G., Loidl P. Bioorg. Med. Chem. Lett. 7:1997;1655.
6. 50 was determined using immunoprecipitated HDAC1. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3003.
7. (a) Tsuji N., Kobayashi M., Nagashima K., Wakisaka Y., Koizumi K. J. Antibiotics. 29:1976;1
8. (b) Yoshida M., Nomura S., Beppu T. Cancer Res. 47:1987;3688.
9. Warrell R.P. Jr., He L.-Z., Richon V., Calleja E., Pandolfi P.P. J. Natl. Cancer Inst. 90:1998;1621.
10. 10.
11. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., Nakanishi O. Proc. Natl. Acad. Sci. U.S.A. 96:1999:4592.
12. (a) Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. J. Biol. Chem. 268:1993;22429
13. (b) Singh S.B., Zink D.L., Polishook J.D., Dombrowski A.W., Darkin-Rattray S.J., Schmatz D.M., Goetz M.A. Tetrahedron Lett. 37:1996;8077.
14. Hajduk P.J., Sheppard G., Nettesheim D.G., Olejniczak E.T., Shuker S.B., Meadows R.P., Steinman D.H., Carrera G.M. Jr., Marcotte P.A., Severin J., Walter K., Smith H., Gubbins E., Simmer R., Holzman T.F., Morgan D.W., Davidsen S.K., Summers J.B., Fesik S.W. J. Am. Chem. Soc. 119:1997;5818.
15. 50 was determined using a mixture of HDAC1 and HDAC2 prepared from nuclear extraction of K562 erythroleukemia cells. This protocol is described in Yoshida M., Kijima M., Akita M., Beppu T. J. Biol. Chem. 265:1990;17174.
16. Jung M., Brosch G., Kölle D., Scherf H., Gerhäuser C., Loidl P. J. Med. Chem. 42:1999;4669.
17. Michaelides M.R., Dellaria J.F., Gong J., Holms J.H., Bouska J.J., Stacey J., Wada C.K., Heyman H.R., Curtin M.L., Guo Y., Goodfellow C.L., Elmore I.B., Albert D.H., Magoc T.J., Marcotte P.A., Morgan D.W., Davidsen S.K. Bioorg. Med. Chem. Lett. 11:2001;1553.
18. Gelb M.H., Svaren J.P., Abeles R.H. Biochemistry. 24:1985;1813.
19. Trimble L.A., Street I.P., Perrier H., Tremblay N.M., Weech P.K., Bernstein M.A. Biochemistry. 32:1993;12560.
20. Patel D.V., Rielly-Gauvin K., Ryono D.E., Free C.A., Smith S.A., Petrillo E.W. Jr. J. Med. Chem. 36:1993;2431.
21. (a) Peet N.P., Burkhart J.P., Angelastro M.R., Giroux E.L., Mehdi S., Bey P., Kolb M., Neises B., Schirlin D. J. Med. Chem. 33:1990;394
22. (b) Boger D.L., Sato H., Lerner A.E., Austin B.J., Patterson J.E., Patricelli M.P., Cravatt B.F. Bioorg. Med. Chem. Lett. 9:1999;265
23. (c) Edwards P.D., Andisik D.W., Strimpler A.M., Gomes B., Tuthill P.A. J. Med. Chem. 39:1996;1112.
24. (a) Walter M.W., Felici A., Galleni M., Soto R.P., Adlington R.M., Baldwin J.E., Frère J.-M., Gololobov M., Schofield C.J. Bioorg. Med. Chem. Lett. 6:1996;2455
25. (b) Christianson D.W., Lipscomb W.N. J. Am. Chem. Soc. 108:1986;4998.
26. Finnin M.S., Donigan J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Nature. 401:1999;188.
27. Boivin J., El Kaim L., Zard S.Z. Tetrahedron. 51:1995;2573.
28. Angelastro M.R., Baugh L.E., Bey P., Burkhart J.P., Chen T.-M., Durham S.L., Hare C.M., Huber E.W., Janusz M.J., Koehl J.R., Marquart A.L., Mehdi S., Peet N.P. J. Med. Chem. 37:1994;4538.
29. max fluorescence plate reader (Molecular Devices, San Diego, CA, USA). Treated cells were compared to vehicle treated cells to determine growth inhibition.
30. Han J.-W., Ahn S.H., Park S.H., Wang S.Y., Bae G.-U., Seo D.-W., Kwon H.-K., Hong S., Lee H.Y., Lee Y.-W., Lee H.-W. Cancer Res. 60:2000;6068.
31. Veale C.A., Bernstein P.R., Bohnert C.M., Brown F.J., Bryant C., Damewood J.R. Jr., Early R., Feeney S.W., Edwards P.D., Gomes B., Hulsizer J.M., Kosmider B.J., Krell R.D., Moore G., Salcedo T.W., Shaw A., Silberstein D.S., Steelman G.B., Stein M., Strimpler A., Thomas R.M., Vacek E.P., Williams J.C., Wolanin D.J., Woolson S. J. Med. Chem. 40:1997;3173.